Q1 26 EPS
$8.26
BEAT +1.35%
Est. $8.15
Q1 26 Revenue
$97.83B
BEAT +1.55%
Est. $96.34B
vs S&P Since Q1 26
-5.7%
TRAILING MARKET
MCK +10.3% vs S&P +16.0%
Market Reaction
Did MCK Beat Earnings? Q1 2026 Results
McKesson kicked off fiscal 2026 on solid footing, posting first-quarter adjusted EPS of $8.26, beating the $8.15 consensus estimate by 1.39%, while revenue of $97.83 billion topped expectations by 1.55% and surged 23.4% year over year. The engine beh… Read more McKesson kicked off fiscal 2026 on solid footing, posting first-quarter adjusted EPS of $8.26, beating the $8.15 consensus estimate by 1.39%, while revenue of $97.83 billion topped expectations by 1.55% and surged 23.4% year over year. The engine behind that top-line growth was unmistakably the U.S. Pharmaceutical segment, which generated $89.95 billion in revenue, a 25% increase driven by higher prescription volumes from retail national accounts and expanding oncology and specialty product distribution. The quarter also featured transformative M&A, as McKesson closed controlling-stake acquisitions in PRISM Vision Holdings and Core Ventures, extending its US Oncology Network to roughly 3,300 providers, though the combined $3.40 billion cash outlay pushed free cash flow negative for the period. Analysts tracking the company's financial resilience have highlighted its strong interest coverage as a stabilizing factor amid broader market volatility. Management responded to the momentum by raising full-year fiscal 2026 adjusted EPS guidance to a range of $37.10 to $37.90, reflecting 12% to 15% year-over-year growth.
Key Takeaways
- • Increased prescription volumes from retail national account customers
- • Growth in distribution of oncology and specialty products, including contributions from acquisitions
- • Higher demand for access solutions in Prescription Technology Solutions
- • Operational efficiencies from cost optimization initiatives in Medical-Surgical Solutions
- • Higher pharmaceutical distribution volumes in the Canadian business
MCK YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
MCK Revenue by Segment
With YoY comparisons, source: SEC Filings
“McKesson had a standout quarter with momentum and growth across the enterprise. We continue to execute against our strategy, delivering for our customers, partners, and patients. Our strong first quarter results included record revenue of $97.8 billion, representing 23% growth compared to the previous year. In addition, we closed the acquisitions of PRISM Vision Holdings and Core Ventures, further expanding our differentiated capabilities in Oncology and Specialty solutions. As a result of the strong first quarter performance and our confidence in the outlook for the remainder of the year, which includes the announced sale of our Norwegian businesses, we are raising our fiscal 2026 Adjusted Earnings per Diluted Share guidance to a range of $37.10 to $37.90.”
— Brian Tyler, Q1 2026 Earnings Press Release
MCK Earnings Trends
MCK vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
MCK EPS Trend
Earnings per share: estimate vs actual
MCK Revenue Trend
Quarterly revenue: estimate vs actual
MCK Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 27 | — | — | — | — | — |
| Q4 26 BEAT FY | $11.57 | $11.69 | +1.04% | $96.30B | -5.02% |
| FY Full Year | $39.01 | $39.11 | +0.25% | $403.43B | -1.24% |
| Q3 26 BEAT | $9.27 | $9.34 | +0.76% | $106.16B | +0.23% |
| Q2 26 BEAT | $9.05 | $9.86 | +8.95% | $103.15B | -0.93% |
| Q1 26 BEAT | $8.15 | $8.26 | +1.35% | $97.83B | +1.55% |